详细信息
背景信息
What is this antibody validated in? Anti-Alpha-synuclein antibody [4D6] - BSA and Azide free (ab1903) is a mouse monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P) in Human samples. What is the molecular weight of Alpha-synuclein? Anti-Alpha-synuclein [4D6] - BSA and Azide free (ab1903) specifically detects a band for Alpha-synuclein (UniProt: P37840) at a molecular weight of 16kDa. Trusted by the scientific community Anti-Alpha-synuclein [4D6] - BSA and Azide free (ab1903) was first used in a scientific publication in 2004 and has been cited over 70 times in peer-reviewed journals. Reviewed by scientists Anti-Alpha-synuclein [4D6] - BSA and Azide free (ab1903) has over 5 independent reviews from customers.
文献引用 (75)
First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease.
首个SAM竞争性G9a抑制剂FLAV-27作为阿尔茨海默病疾病修饰疗法。
Perivascular spread of CSF-derived α-synuclein oligomers drives region-specific Parkinson's-like pathology.
脑脊液衍生的α-突触核蛋白寡聚体在血管周围扩散，导致区域特异性的帕金森样病理。
Development of human targeted extracellular vesicles loaded with shRNA minicircles to prevent parkinsonian pathology.
开发载有 shRNA 微环的人类靶向细胞外囊泡，以预防帕金森氏症病理
Lysophosphatidylcholine promoting α-Synuclein aggregation in Parkinson's disease: disrupting GCase glycosylation and lysosomal α-Synuclein degradation.
溶血磷脂酰胆碱促进帕金森病中α-突触核蛋白的聚集：破坏GCase糖基化和溶酶体α-突触核蛋白的降解
Cannabidiol as a multifaceted therapeutic agent: mitigating Alzheimer's disease pathology and enhancing cognitive function.
大麻二酚作为一种多方面的治疗剂：减轻阿尔茨海默病病理并增强认知功能
Regulation of mitochondrial dynamics and function by melatonin type 1 receptor in parkinson's disease.
褪黑素1型受体在帕金森病中对线粒体动力学和功能的调节。
Manganese exposure induces parkinsonism-like symptoms by Serpina3n-TFEB-v/p-ATPase signaling mediated lysosomal dysfunction
锰暴露通过 Serpina3n-TFEB-v/p-ATPase 信号介导的溶酶体功能障碍诱发帕金森病样症状
Competing chaperone pathways in α-synuclein disaggregation and aggregation dynamics.
α-突触核蛋白解聚和聚集动力学中的竞争性分子伴侣通路。
The Interplay Between CB(2) and NMDA Receptors in Parkinson's Disease.
CB(2)受体与NMDA受体在帕金森病中的相互作用。
PRNP E146G mutation inherited prion disease: distinctive clinical, pathological and fluid biomarker features.
PRNP E146G 突变遗传性朊病毒病：独特的临床、病理和体液生物标志物特征
- 1
- 2
- 3
- 4
- 5
- 6
- 8